JAMA. 2016 Aug 16;316(7):722-33. doi: 10.1001/jama.2016.11136.

Among postmenopausal women with osteoporosis, the use of subcutaneous abaloparatide, compared with placebo, reduced the risk of new vertebral and nonvertebral fractures over 18 months. Further research is needed to understand the clinical importance of RD, the risks and benefits of abaloparatide treatment, and the efficacy of abaloparatide vs other osteoporosis treatments.

Autor: Miller PD, Hattersley G, Riis BJ, Williams GC, Lau E, Russo LA, Alexandersen P, Zerbini CA, Hu MY, Harris AG, Fitzpatrick LA, Cosman F, Christiansen C; ACTIVE Study Investigators

Leave a Reply

Tu dirección de correo electrónico no será publicada. Los campos obligatorios están marcados con *

  • Nueve + dieciocho =